Abstract 11161: Comparison of Percutaneous Mitral Valve Repair in Patients with Normal vs Severely Reduced Ejection Fraction

Abstract

Introduction: Percutaneous mitral valve repair (PMVR) has been established as a suitable alternative to mitral valve surgery in patients with severe mitral regurgitation (MR). Patients with severely decreased ejection fraction (EF≤ 30%) constitute a higher risk group for adverse outcomes and peri-operative mortality. Hypothesis: We sought to examine the efficacy and safety of MitraClip implantation in severe heart failure patients in comparison to patients with preserved LV function. Methods: Single-center, retrospective study of patients undergoing PMVR between January 2015 and December 2020. All patients were followed up for 30 days. Baseline and procedural characteristics as well as short term outcomes of all-cause mortality, heart failure hospitalizations, stroke, new atrial fibrillation, new pacemaker placement, and improvement in MR severity ≥2 grades and NYHA class were assessed. Results: Among 86 patients undergoing PMVR, 26 had severely decreased EF. Patients with severely decreased EF were younger and more likely to have diabetes and mixed pathology MR. Additionally they received guideline directed medical therapy at higher rates. Characteristics of the population are shown in Table 1. At 30 days, no significant difference was observed between the two groups in regards to all-cause mortality, HF hospitalization, stroke, new atrial fibrillation, new pacemaker placement, and improvement in MR severity ≥2 grades and NYHA class. Conclusions: PMVR with the MitraClip system is feasible and a safe option for patients with MR and severely reduced EF.